deltatrials
Completed PHASE2 NCT00185796

TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD

Total Lymphoid Irradiation and Anti-Thymocyte Globulin as Conditioning for Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for the Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)

Sponsor: National Institutes of Health (NIH)

Conditions Blood Cancer Myelodysplastic Syndromes Myeloproliferative Disorders
Interventions Anti-Thymocyte Globulin as Conditioning (ATG) Total Lymphoid Irradiation (TLI)
Updated 5 times since 2017 Last updated: Mar 16, 2015 Started: Jul 31, 2004 Primary completion: Apr 30, 2014 Completion: Feb 28, 2015

This PHASE2 trial investigates Blood Cancer and Myelodysplastic Syndromes and is currently completed. National Institutes of Health (NIH) leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institutes of Health (NIH)
  • Stanford University
Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Stanford, United States